GlassScriptPhysician profile
Ortelio Bosch
NPI 1629046842
$5,111.19
in general payments reported to CMS, 2019-2025
28 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $796 · 2021: $882 · 2022: $645 · 2023: $760 · 2024: $250 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,255.03 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Forte Bio-Pharma LLC | $575.90 | 2020-2024 | Prolate, Nalocet |
| Abbott Laboratories | $562.78 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $426.17 | 2019-2024 | Belbuca, Xtampza |
| Curonix LLC | $141.76 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.28 | 2020-2023 | Relistor |
| Spr Therapeutics, INC | $136.62 | 2025 | Sprint Pns System |
| Sentynl Therapeutics, INC. | $115.56 | 2019 | |
| Nevro Corp. | $112.14 | 2019-2023 | Senza |
| Pfizer INC. | $107.03 | 2019-2021 | |
| Medtronic, INC. | $89.81 | 2023 | Intellis Adaptivestim |
| Grt US Holding, INC. | $71.79 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $61.00 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $40.93 | 2019-2021 | |
| Vertos Medical, INC. | $38.94 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $29.56 | 2023-2024 | Tirosint, Licart, Tirosint |
| Spinal Simplicity, LLC | $25.17 | 2024 | Ha Minuteman G3-R |
| Baudax Bio INC. | $24.74 | 2020 | |
| Redhill Biopharma INC. | $22.61 | 2020 | |
| Scilex Pharmaceuticals INC. | $18.74 | 2019 | |
| Daiichi Sankyo INC. | $18.39 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.95 | 2023 | Iovera, Zilretta |
| Almatica Pharma LLC | $16.51 | 2021 | |
| Medtronic USA, INC. | $15.61 | 2020 | |
| Mdd US Operations, LLC | $13.68 | 2019 | |
| Horizon Therapeutics Plc | $13.03 | 2021 | |
| Stimwave Technologies Incorporated | $12.23 | 2019 | |
| Shionogi INC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ortelio Bosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.